Skip to main content

Health condition · Clinically reviewed

Haemangioblastoma, surgery, radiosurgery and belzutifan for VHL.

A rare benign brain, spine and retinal tumour. Most are cured by surgery. Those linked to von Hippel-Lindau need a lifelong specialist plan.

A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, the VHL Alliance UK and peer-reviewed neuro-oncology sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including stereotactic radiosurgery and belzutifan for VHL-associated disease.

Key facts

Haemangioblastoma at a glance.

The essentials in plain English - what it is, where it grows, and how it is treated in the UK today.

  • What it is

    A rare benign vascular tumour of the central nervous system, WHO grade 1, arising in the cerebellum, brainstem, spinal cord or retina.

  • How common

    About 2 per cent of intracranial tumours. Most commonly found in the posterior fossa in adults aged 30 to 60.

  • Sporadic vs VHL

    Around 60 to 80 per cent are sporadic. The rest arise as part of von Hippel-Lindau syndrome, an autosomal-dominant condition.

  • Presentation

    Headache, imbalance, nausea and vomiting are typical when a cerebellar tumour blocks CSF flow and raises intracranial pressure.

  • Key investigation

    Contrast MRI of the brain and whole spine is the standard imaging - referred and reported through specialist neuro-oncology.

  • Curative option

    Complete surgical resection is curative for most sporadic tumours. Radiosurgery and belzutifan support VHL-related disease.

Why this guide matters

A rare tumour with a modern plan.

Haemangioblastoma is uncommon, but the pathway is well-defined. The three points below shape everything else on this page.

  • Surgery is often curative

    Complete microsurgical resection cures most sporadic tumours - specialist commissioned neurosurgery is the gold standard.

  • Radiosurgery has widened options

    Gamma Knife and LINAC radiosurgery treat tumours where open surgery carries high morbidity, or manage residual disease.

  • Belzutifan changes VHL care

    A NICE-approved oral HIF-2 alpha inhibitor now shrinks VHL-associated tumours and delays or avoids surgery.

How the diagnosis is made

From first symptoms to a personalised plan.

The steps a UK neurology or neurosurgery team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    History and family history

    A careful look for red flags of raised intracranial pressure and any family history of VHL, retinal or renal tumours.

  2. 02

    Assessing

    Neurological examination

    Ataxia, coordination, cranial-nerve and gait testing, plus fundoscopy to look for retinal angiomas.

  3. 03

    Assessing

    Contrast MRI brain and spine

    The definitive imaging - referred and reported through specialist neuro-oncology. Whole-spine imaging is important because tumours may be multiple.

  4. 04

    Confirming

    CT and retinal imaging

    CT can show calcification and hydrocephalus. Specialist ophthalmology imaging looks for retinal haemangioblastomas.

  5. 05

    Confirming

    Genetic testing for VHL

    VHL gene testing on chromosome 3p25, with cascade testing for at-risk relatives - referred through specialist commissioned clinical genetics.

  6. 06

    Preparing

    Full-body VHL surveillance

    If VHL is confirmed, lifelong screening for renal, adrenal, pancreatic and inner-ear tumours is arranged through specialist commissioned services.

  7. 07

    Preparing

    Neuro-oncology MDT plan

    A specialist commissioned MDT of neurosurgery, neuro-oncology, genetics and ophthalmology agrees the safest personalised plan.

Typical timeline: imaging within days, MDT plan within weeks.

Symptoms

What haemangioblastoma feels like.

Symptoms usually reflect the tumour location - most commonly the cerebellum, sometimes the spinal cord or retina. Features often build gradually.

  • Headache and morning nausea

    Classic features of raised intracranial pressure from a posterior-fossa mass or hydrocephalus.

  • Ataxia and clumsy coordination

    Unsteady gait, past-pointing and dysdiadochokinesia point to a cerebellar tumour.

  • Vomiting and papilloedema

    Persistent vomiting with swollen optic discs signals rising pressure and needs urgent imaging.

  • Spinal cord syndromes

    Myelopathy or radiculopathy - weakness, sensory change or bladder involvement - can point to a cord tumour.

  • Retinal changes and vision loss

    Retinal haemangioblastomas can leak fluid and cause retinal detachment. Fundoscopy is essential.

  • Polycythaemia

    About one in ten tumours secrete erythropoietin, raising the red-cell count and haematocrit.

  • Multiple lesions and family history

    More than one lesion, or any lesion in a young patient with a family history, strongly suggests VHL.

  • Red flag - acute hydrocephalus

    Sudden severe headache, drowsiness or reduced consciousness needs emergency neurosurgical assessment.

Treatment

How haemangioblastoma is treated in the UK.

Surgery is the mainstay. Radiosurgery, belzutifan, embolisation and lifelong VHL surveillance complete the picture. All delivered through specialist commissioned centres.

  • Observation

    Small, asymptomatic tumours can be monitored with serial MRI under specialist neuro-oncology follow-up.

  • Surgical resection

    Complete microsurgical removal is curative for most sporadic tumours - the gold standard, delivered by specialist commissioned neurosurgery.

  • Stereotactic radiosurgery

    Gamma Knife or LINAC radiosurgery is used for tumours where surgery carries high morbidity, for residual or recurrent disease. See our treatment guide.

  • Belzutifan (Welireg)

    An oral HIF-2 alpha inhibitor NICE-approved in 2023 for VHL-associated tumours - shrinks CNS, renal and pancreatic lesions and delays surgery.

  • Pre-surgical embolisation

    Selective embolisation of feeding arteries can reduce blood loss before resection of highly vascular tumours.

  • VHL specialist centres

    Cases are managed at specialist commissioned UK centres including Great Ormond Street, Cambridge and Birmingham, in partnership with the VHL Alliance UK.

  • Lifelong VHL surveillance

    Annual imaging, retinal review, biochemistry and audiology are delivered through specialist commissioned VHL protocols.

  • Genetic counselling

    Formal counselling and cascade testing for relatives is part of every VHL diagnosis - referred through specialist commissioned genetics.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, specialist society standards and international neuro-oncology consensus, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your neurologist, neurosurgeon or specialist genetic team knows your history and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Belzutifan for treating von Hippel-Lindau disease-associated tumours (TA904).

  • VHL Alliance UK. Clinical surveillance guidelines for VHL disease.

  • WHO Classification of Tumours of the Central Nervous System, 5th edition.

  • NHS England. Highly specialised service for complex neurofibromatosis and VHL.

Red flags

When to seek urgent attention.

Most haemangioblastomas are managed in a planned, stepwise way. These are the situations where care must be brought forward.

  • Acute hydrocephalus

    Sudden severe headache, vomiting or drowsiness with a posterior-fossa tumour is a neurosurgical emergency.

  • Rapid visual loss

    A retinal haemangioblastoma with sudden vision loss suggests haemorrhage or retinal detachment and needs urgent ophthalmology review.

  • New spinal weakness or bladder change

    Cord compression from a spinal tumour needs urgent MRI and specialist neurosurgical assessment.

  • Family history of VHL

    Any young patient with a haemangioblastoma and a family history of VHL, renal or retinal tumours needs specialist commissioned genetic review.

  • Multiple lesions on MRI

    More than one CNS tumour is a strong pointer to VHL and mandates genetic testing and full-body screening.

  • Unexplained polycythaemia

    A raised haematocrit without another cause should prompt a search for an EPO-secreting tumour.

  • New phaeochromocytoma symptoms

    Headaches, palpitations and hypertensive spikes in a patient with VHL need urgent adrenal workup.

  • Rising renal lesion in VHL

    A growing renal mass on VHL surveillance imaging needs urgent urology and oncology review.

  • Balance or hearing change

    A new endolymphatic-sac tumour in VHL can cause vertigo and deafness and needs specialist ENT assessment.

Living with it

A rare condition, with a strong support network.

Four things that make the biggest difference over time - staying on the surveillance schedule, joining the VHL Alliance UK, thinking about family testing, and planning rehabilitation.

A quiet reminder

Surveillance is the single most powerful tool.

Catching a small, treatable tumour on annual imaging is far better than finding a large one after symptoms appear.

  1. 01 Screening

    Stay on the VHL schedule

    If you have VHL, lifelong annual surveillance is the single most important thing you can do - it catches tumours when they are small and treatable.

  2. 02 Support

    Join the VHL Alliance UK

    A national patient community with clinician links and up-to-date guidance is a huge help for families adjusting to a genetic diagnosis.

  3. 03 Family

    Consider cascade testing

    First-degree relatives of anyone with VHL can be offered predictive testing through specialist commissioned clinical genetics.

  4. 04 Recovery

    Rehabilitation after surgery

    Cerebellar surgery often needs a period of physiotherapy and vestibular rehabilitation - most people make an excellent recovery.

Frequently asked

Everything we get asked about haemangioblastoma.

Quick answers on diagnosis, surgery, radiosurgery, belzutifan and VHL surveillance.

  • What is a haemangioblastoma?

    A rare benign vascular tumour of the central nervous system, WHO grade 1. It most often grows in the cerebellum but can also arise in the brainstem, spinal cord or retina. Most tumours are sporadic, but around 20 to 40 per cent occur as part of von Hippel-Lindau syndrome, an inherited condition.

  • How is a haemangioblastoma diagnosed?

    Contrast MRI of the brain and whole spine is the definitive test, alongside a full neurological and eye examination. If there are multiple tumours, a family history or a young age at diagnosis, VHL genetic testing is arranged through specialist commissioned clinical genetics.

  • Is a haemangioblastoma cancer?

    No. It is a WHO grade 1 benign tumour and does not spread to distant organs. However, it can cause serious problems by pressing on the brainstem, cerebellum or spinal cord, and VHL-associated cases need lifelong surveillance for other tumours.

  • What is the treatment?

    The mainstay is complete microsurgical resection, which is curative for most sporadic tumours. Stereotactic radiosurgery is used when surgery carries high morbidity or for residual and recurrent disease. Belzutifan is a NICE-approved oral drug for VHL-associated tumours.

  • What is belzutifan and who is it for?

    Belzutifan (Welireg) is an oral HIF-2 alpha inhibitor NICE-approved in 2023 for VHL-associated tumours including CNS haemangioblastomas, clear-cell renal cell carcinoma and pancreatic neuroendocrine tumours. It is prescribed through specialist commissioned VHL centres and can shrink tumours and delay or avoid surgery.

  • What screening do I need if I have VHL?

    Lifelong annual surveillance under the VHL protocol, delivered through specialist commissioned centres. This includes MRI of the brain and spine, retinal review, renal and adrenal imaging, biochemistry for phaeochromocytoma and periodic audiology for endolymphatic-sac tumours.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.